Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
Loading...
Embargo End Date
ICR Authors
Authors
Glynn, D
Bliss, J
Brunt, AM
Coles, CE
Wheatley, D
Haviland, JS
Kirby, AM
Longo, F
Faria, R
Yarnold, JR
Griffin, S
Bliss, J
Brunt, AM
Coles, CE
Wheatley, D
Haviland, JS
Kirby, AM
Longo, F
Faria, R
Yarnold, JR
Griffin, S
Document Type
Journal Article
Date
2022-11-17
Date Accepted
2022-10-18
Abstract
PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. METHODS: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. RESULTS: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. CONCLUSIONS: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system.
Citation
Breast Cancer Research and Treatment, 2022,
Source Title
Breast Cancer Research and Treatment
Publisher
SPRINGER
ISSN
0167-6806
eISSN
1573-7217
1573-7217
1573-7217
Collections
Research Team
Clin Trials & Stats Unit